Drug Evaluation Committee Information on the "Workshop for Promoting QMS Implementation: Experiencing the Approaches to Organizational Issues" Event for Pharmaceutical Companies/CROs (Face-to-Face: March 4, 2025)
January 22, 2025
The Clinical Evaluation Subcommittee of the Drug Evaluation Committee of the Japan Pharmaceutical Manufacturers Association (JMPMA) is pleased to announce a workshop aimed at promoting QMS implementation at sponsors and CROs. This workshop will be held to promote QMS implementation by sponsors and CROs. Approaches to QMS Implementation by Clinical Research Sponsors - Fostering a Culture of Quality and Demonstrating Leadership and is planned as a forum for dialogue on solutions to QMS implementation issues.
Through this workshop, we aim for participants to take away tips for QMS implementation and promotion through dialogue incorporating the perspective of "Fostering a Culture of Quality and Demonstrating Leadership".
For more information on how to register and details of the workshop, QMS Implementation Promotion Workshop: Experiencing Approaches to Organizational Issues We look forward to the participation of not only QMS professionals, but also monitors, study planners, and many others.
The series of activities by the Clinical Evaluation Task Force related to quality management that have been conducted for the past several years, including this workshop, will be completed this year. We welcome those who have already participated in other projects, so please take advantage of this opportunity.
Registration deadline: Friday, February 21, 2025
How to register: Please register via the following URL or QR code.
URL: https://form.qooker.jp/Q/auto/ja/25TF2QMSwspre/QMSWSpre/
| Date & Time】 【Date & Time】 【Venue |
Tuesday, March 4, 2025, 13:15 - 16:30 |
|---|---|
| Venue】 【Venue |
Nihonbashi Life Science Building, 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo |
| Participation |
Face-to-face |
| Participation fee】 【Participation fee】 【Applicants】 【Target |
Free of charge |
| 【target group】 |
People involved in clinical trials at pharmaceutical companies/CROs
|
| Conditions for participation |
|
| Number of participants] [Number of applicants] [Number of participants |
Up to 36 people |
